Lymphoma Read with the experts

Similar documents
Update in Lymphoma Imaging

Lugano classification: Role of PET-CT in lymphoma follow-up

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

PET/CT Frequently Asked Questions

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Abstracting Hematopoietic Neoplasms

Hodgkin's Lymphoma. Symptoms. Types

PET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging

L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?

Clinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Lymphatic System Disorders

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Pathology of Hematopoietic and Lymphoid tissue

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

New Visions in PET: Surgical Decision Making and PET/CT

Clinical indications for positron emission tomography

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphatic system component

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Yiyan Liu. 1. Introduction

PET-imaging: when can it be used to direct lymphoma treatment?

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Change Summary - Form 2018 (R3) 1 of 12

ASPS Recommended Insurance Coverage Criteria for Third- Party Payers

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT LYMPHOMA CHAPTER 11B REVISED: SEPTEMBER 2016

Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma

STAGING AND FOLLOW-UP STRATEGIES

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2

Melanoma Case Scenario 1

FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification

Hematologic Malignancies of the Liver : Spectrum of Disease. Zhou Jian

The Role of PET / CT in Lung Cancer Staging

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia

1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page

Melanoma Case Scenario 1

Positron Emission Tomography in Lung Cancer

NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/CT

FDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.

Head and Neck: DLBCL

Pediatric Oncology. Vlad Radulescu, MD

Pathology of Hematopoietic and Lymphoid tissue

Patient underwent hemicolectomy: 7 x 4.5 cm intusscepted segment of ileum in colon - mucosal

Patient Case Studies & Panel Discussion

ARRO Case: Pediatric High Risk Classical Hodgkin Lymphoma

Immunopathology of Lymphoma

Diagnosis and patient pathway in lymphomas

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

Imaging in gastric cancer

NAACCR Webinar Series 1

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

UK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky

Indium-111 Zevalin Imaging

2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA

Zydelig. Zydelig (idelalisib) Description

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori

Non-Hodgkin lymphoma

Indolent Lymphomas: Current. Dr. Laurie Sehn

Approach to Core Biopsy Specimens

ISPUB.COM. Primary Cutaneous Anaplastic Large Cell Lymphoma Long-term Management with Low Dose Methotrexate. S Parker INTRODUCTION

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Melanoma Quality Reporting

ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Zydelig. Zydelig (idelalisib) Description

Pediatric Lymphoma Update from the Children s Oncology Group

FieldStrength. Leuven research is finetuning. whole body staging

Understanding the Diagnostic and Prognostic Role of Imaging in the Evaluation of an Anterior Mediastinal Mass

Deppen S, et al. Annals of Thoracic Surgery 2011;92:

Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Peripheral blood Pleural effusion in a cat

Radiology Pathology Conference

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

Sally Barrington Martin Hutchings

IBD-Related Lymphoma

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Lymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.

Transcription:

Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology

Learning Objectives Recognize common pitfalls and artifacts in interpreting PET/CT in lymphoma Discuss and apply current recommendations for performing a standardized interpretation of PET/CT in response assessment of lymphoma Identify common patterns of spread by lymphoma and recognize subtypes of lymphoma that have variable or low FDG uptake

Case 1

22 yom Large B-Cell Lymphoma PET-CT performed 2 days after starting chemotherapy

On this PET-CT performed 2 days after starting chemotherapy, the most likely explanation for the low FDG uptake in the mediastinal mass is: A. Large B-cell lymphomas are not reliably FDG avid B. The histology of the mediastinal mass was not adequately sampled prior to starting chemotherapy C. The bulk of the mass is comprised of inflammatory tissue D. FDG uptake is suppressed due to 2 days of chemotherapy

?

On this PET-CT performed 2 days after starting chemotherapy, the most likely explanation for the low FDG uptake in the mediastinal mass is: A. Large B-cell lymphomas are not reliably FDG avid B. The histology of the mediastinal mass was not adequately sampled prior to starting chemotherapy C. The bulk of the mass is comprised of inflammatory tissue D. FDG uptake is suppressed due to 2 days of chemotherapy

22 yom Large B-Cell Lymphoma Restaging PET-CT after 6 cycles of chemotherapy

Restaging PET/CT after 6 cycles of chemotherapy

Baseline CT Restaging PET/CT Post 6 cycles of chemo

?

The most likely explanation for the high FDG uptake in the residual mediastinal mass is: A. Thymic hyperplasia B. Metastatic lesion from another new primary tumor C. Post-chemotherapy inflammation D. Residual active lymphoma

The most likely explanation for the high FDG uptake in the residual mediastinal mass is: A. Thymic hyperplasia B. Metastatic lesion from another new primary tumor C. Post-chemotherapy inflammatory tissue D. Residual active lymphoma

Mini-sternotomy after PET-CT Final pathology: Rests of normal thymic tissue No lymphoma present in specimen Findings at pathology consistent with thymic hyperplasia

22 yom Large B- Cell Lymphoma Follow-up PET-CT 3 months post sternotomy

3 months after surgical excision with no further treatment: PET Interpretation: No active lymphoma

Case 1 Teaching Points FDG avid hyperplastic thymic tissue is commonly seen in children and young adults in the early months following completion of chemotherapy As the thymus normally involutes with aging, the morphologic appearance of thymic hyperplasia can be quite variable ranging from homogeneous and curvilinear, to heterogenous, patchy, asymmetric, and focal.

Case 1 Teaching Points Lymphomas can arise within or near the thymus. In such cases, residual active lymphoma cannot always be excluded as the cause of a post-chemotherapy residual hypermetabolic mass without surgical or biopsy proof. While uncommon, high FDG uptake in a postchemotherapy residual mass may be due to inflammation

14 year old with anaplastic lymphoma Baseline 4 months post-chemo (NED)

Post - Chemotherapy Thymic Hyperplasia

Post - Chemotherapy Thymic Hyperplasia

Post - Chemotherapy Thymic Hyperplasia

Recurrent Lymphoma and Thymic Hyperplasia

Recurrent Lymphoma and Thymic Hyperplasia

Recurrent Lymphoma and Thymic Hyperplasia

Thymus Activity on PET The degree of FDG uptake in thymic hyperplasia is variable but typically greater than or equal to liver activity

Case 2

History 52-year-old woman with Hodgkin lymphoma referred for a restaging PET/CT after 2 cycles of chemotherapy

Baseline Post 2 cycles chemotherapy Marrow Bx: +Diffuse Infiltration? Worse, Stable, Better?

Based on the images shown, the BEST interpretation of the PET findings is: A. Worsening of active lymphoma B. Stable active lymphoma C. Improved but residual active lymphoma D. Resolved, no active lymphoma E. Indeterminate for residual active lymphoma

Based on the images shown, the BEST interpretation of the PET findings is: A. Worsening of active lymphoma B. Stable active lymphoma C. Improved but residual active lymphoma D. Resolved, no active lymphoma E. Indeterminate for residual active lymphoma

Baseline PET/CT Post 2 cycles chemotherapy

Baseline L2 body Post- 2 cycles chemo

Baseline L2 body Post- 2 cycles chemo

Baseline L2 body Post- 2 cycles chemo

Baseline para-aortic node Post- 2 cycles chemo

Baseline para-aortic node Post- 2 cycles chemo

Baseline para-aortic node Post- 2 cycles chemo

Based on the images shown, the BEST interpretation of the PET findings is: A. Improved but residual active lymphoma in the left paraaortic lymph node B. Improved but residual active lymphoma in the L4 vertebral body C. No active lymphoma in the L4 vertebral body nor in the left paraaortic lymph node. D. Worsening of active lymphoma (treatment failure)

Based on the images shown, the BEST interpretation of the PET findings is: A. Improved but residual active lymphoma in the left paraaortic lymph node B. Improved but residual active lymphoma in the L4 vertebral body C. No active lymphoma in the L4 vertebral body nor in the left paraaortic lymph node. Reactive marrow hyperplasia in the skeleton that was not involved by lymphoma. D. Worsening of active lymphoma (treatment failure)

Case 2 Final Diagnosis No active lymphoma in the L4 vertebral body nor in the left paraaortic lymph node. Marrow hyperplasia throughout the skeleton.

61F, Hodgkin Lymphoma Baseline Post 2 cycles chemo Post 6 cycles chemo Marrow Bx: +Diffuse Infiltration Treated lesions and Reactive Marrow Probably no active disease Marrow Bx: Negative No active disease

Case 2 Teaching Points Marrow hyperplasia on PET/CT is commonly seen in patients receiving granulocyte colony stimulating factor (GCSF) which is given concurrently with chemotherapy. Rebound marrow hyperplasia on PET/CT can also be seen in the early weeks to months after completing chemotherapy.

Case 2 Teaching Points The presence of diffuse marrow activity on a followup PET/CT should not be misinterpreted as tumor involvement, particularly when all previously known sites of disease have resolved.

Non-Hodgkin s Lymphoma Restaging

Marrow and Splenic Hyperplasia due to colony stimulating factors

PET/CT Initial Staging NSCLC Diffuse marrow activity presumed due to tumor GCSF production

Baseline PET/CT Post 4 cycles chemotherapy

Baseline PET/CT Post 4 cycles chemotherapy

Case 3

52-year-old with non-small cell lung cancer undergoing presurgical evaluation

The BEST interpretation of the PET findings is: A. Right lung cancer and a second primary neoplastic process such as lymphoma involving the left axilla B. Right lung cancer and unrelated inflammatory process involving the left axilla and left deltoid C. Right lung cancer and contralateral left axillary nodal metastases D. Right lung cancer and infiltrated dose in the left arm

The BEST interpretation of the PET findings is: A. Right lung cancer and a second primary neoplastic process such as lymphoma involving the left axilla B. Right lung cancer and unrelated inflammatory process involving the left axilla and left deltoid C. Right lung cancer and contralateral left axillary nodal metastases D. Right lung cancer and infiltrated dose in the left arm

Case 3 Diagnosis Right lung cancer and unrelated inflammatory process involving the left axilla and left deltoid. The patient had influenza vaccination in the left deltoid 3 days prior to the PET/CT

Flu shot in left arm 3 days before PET/CT

Case 3 Teaching Points Recent vaccinations can result in FDG uptake at the injection site and within regional lymph nodes The regional lymph nodes may or may not appear pathologically enlarged Dose infiltration can result in FDG uptake within the draining sentinel lymph nodes on the side of injection. The lymph nodes are typically NOT enlarged and FDG uptake within lymphatic vessels may be seen distal to the injection site.

Dose infiltration in right antecubital fossa

Follicular lymphoma in left arm and axilla

Case 4

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles

After 6 cycles of chemotherapy, which of the following is the BEST overall impression of the PET-CT findings: A. No active lymphoma B. Indeterminate for residual active lymphoma C. Suspicious for residual active lymphoma D. New marrow involvement by lymphoma

After 6 cycles of chemotherapy, which of the following is the BEST overall impression of the PET-CT findings: a. No active lymphoma b. Indeterminate for residual active lymphoma c. Suspicious for residual active lymphoma d. New marrow involvement by lymphoma

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles 5weeks later Indeterminate

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles 5weeks later

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles 5weeks later

42 yow Non-Hodgkin s Lymphoma Baseline 6 cycles 5weeks later?

5 weeks after the post cycle 6 PET-CT, which of the following is the BEST overall impression of the PET-CT findings: A. No active lymphoma B. Indeterminate for recurrent active lymphoma C. Recurrent active lymphoma D. New marrow involvement by lymphoma

5 weeks after the post cycle 6 PET-CT, which of the following is the BEST overall impression of the PET-CT findings: A. No active lymphoma B. Indeterminate for recurrent active lymphoma C. Recurrent active lymphoma D. New marrow involvement by lymphoma

NCCN recommends using which of the following PET imaging criteria to assess treatment response and determine further treatment options in Hodgkin lymphoma? a. PERCIST b. International working group response criteria c. Standardized uptake value criteria d. Deauville criteria e. None of the above: interpretation criteria are not included in NCCN guidelines

NCCN recommends using which of the following PET imaging criteria to assess treatment response and determine further treatment options in Hodgkin lymphoma? a. PERCIST b. International working group response criteria c. Standardized uptake value criteria d. Deauville criteria e. None of the above: interpretation criteria are not included in NCCN guidelines

Deauville Criteria for PET Guided Response Assessment of Lymphoma

Deauville Criteria for PET Guided Response Assessment of Lymphoma

Non-Hodgkin s Lymphoma Baseline 6 cycles 5weeks later Deauville 3 or 4 Deauville 4 or 5

Non-Hodgkin s Lymphoma Baseline 2 cycles 6 cycles

Non-Hodgkin s Lymphoma Baseline 2 cycles 6 cycles

Non-Hodgkin s Lymphoma Baseline 2 cycles 6 cycles

Non-Hodgkin s Lymphoma Baseline 2 cycles 6 cycles

Non-Hodgkin s Lymphoma Baseline 2 cycles 6 cycles

Bleomycin induced pneumonitis Baseline 2 cycles 6 cycles Deauville 2 Deauville 2, X

The Deauville criteria is included in the NCCN guidelines for BOTH Hodgkin and Non-Hodgkin lymphoma management algorithms? a. True b. False

The Deauville criteria is included in the NCCN guidelines for BOTH Hodgkin and Non-Hodgkin lymphoma management algorithms? a. True b. False The Deauville criteria is included in the NCCN guidelines for Hodgkin and DLBCL (2015)

The Deauville criteria is included in the NCCN guidelines for Hodgkin and DLBCL (2015)

The Deauville criteria is included in the NCCN guidelines for Hodgkin and DLBCL (2015)

Which one of the following types of lymphomas is the LEAST likely to be 18 F-FDG-avid? a. Diffuse large B cell b. Follicular c. Marginal zone/ mucosa-associated lymphoid tissue d. Hodgkin e. Mantle Cell

Which one of the following types of lymphomas is the LEAST likely to be 18 F-FDG-avid? a. Diffuse large B cell b. Follicular c. Marginal zone/ mucosa-associated lymphoid tissue d. Hodgkin e. Mantle cell

Newly Diagnosed MALT Lymphoma of the Stomach

Newly Diagnosed MALT Lymphoma of the Stomach

Newly Diagnosed MALT Lymphoma of the Stomach

Case 5

MJM 60 yo male presented with increasing fatique, night sweats and adenopathy. Labs revealed elevated WBC with lymphocyte predominance, anemia, thrombocytopenia and elevated LDH. Flow cytometry confirmed CLL On exam patient had diffuse adenopathy and dominant neck mass PET scan done to help stage disease and guide biopsy

MJM Biopsy of neck mass confirmed transformation of CLL to DLBCL (Richter s Transformation). Patient received 4 cycles of RCHOP with resolution of all PET avid adenopathy Autologous stem cell transplant In remission after 3 years Goal of treatment was to cure the aggressive lymphoma; CLL is likely to relapse in future

Thank you and Questions?

Bonus Cases (Interpretation Pitfalls)

42 yo man, mediastinal adenopathy, suspected lymphoma

Final Diagnosis: Disseminated Sarcoidosis

19 yow with fevers, night sweats, remote h/o Hodgkin s

Acute EBV Infection (confirmed by serum titer)

Repeat (new baseline) PET-CT 6 months post EBV Infection

PET/CT Restaging Lymphoma??Recurrence

PET/CT Restaging Lymphoma Brown Adipose Tissue

Brown Adipose Tissue Exists in animals, infants, and adults. Mitochondria rich and highly vascular Sympathetic nervous system activity significantly increases glucose uptake by BAT. FDG uptake is felt to be due to non-shivering thermoregulation caused by sympathetic stimulation BAT on PET scans is more commonly seen in younger, thin, women and seen more frequently during winter months

Brown Adipose Tissue FDG uptake in brown adipose tissue can be dramatically reduced by pre-medication with a benzodiazepine or beta blocker Consider pre-medication in any young patient (up to age 40) Oral alprazolam 0.5 mg or diazepam 5 mg given 60 minutes prior to FDG injection CT part of PET-CT helps avoid misinterpretations

Thank you